InnoCare Pharma Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INCPF research report →
About the company
InnoCare Pharma Limited is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments, primarily targeting cancer and autoimmune disorders. A key product in their portfolio is Orelabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. This therapy targets various relapsed or refractory blood cancers, including chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, diffuse large B-cell lymphoma (MCD subtype), central nervous system lymphoma, and is also being explored in combination with MIL-62.
- CEO
- Jisong Cui
- IPO
- 2021
- Employees
- 1,089
- HQ
- Beijing, CN
Price Chart
- Market Cap
- $2.32B
- P/E
- 28.25
- P/S
- 6.76
- P/B
- 2.72
- EV/EBITDA
- 18.67
- Div Yield
- 0.00%
- Gross Margin
- 90.36%
- Op Margin
- 23.70%
- Net Margin
- 28.78%
- ROE
- 10.12%
- ROIC
- 6.18%
- Revenue
- $2.30B · 127.62%
- Net Income
- $625.89M · 242.04%
- EPS
- $0.36 · 238.46%
- Op Income
- $440.63M
- FCF YoY
- 129.48%
- 52W High
- $3.26
- 52W Low
- $1.55
- 50D MA
- $1.55
- 200D MA
- $2.01
- Beta
- 0.36
- Avg Volume
- 526.8
Get TickerSpark's AI analysis on INCPF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our INCPF coverage
Recent articles, reports, and earnings notes.
No research on INCPF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate INCPF report →Similar companies
Peers in the same neighborhood.